Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Droxidopa Capsules, 100 mg, 200 mg and 300 mg. Droxidopa Capsules are generic version of Lundbeck NA's Northera Capsules.
The product will be launched immediately.
The approved product has an estimated market size of US$ 352 million for the twelve months ending
December 2020, according to IQVIA. Droxidopa is indicated for the treatment of orthostatic dizziness
and lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension caused by
primary autonomic failure, dopamine beta-hydroxylase deficiency and non-diabetic autonomic
This is the 24th ANDA to be approved out of Unit-X formulation facility in Hyderabad, India used for
manufacturing oral products. Aurobindo now has a total of 469 ANDA approvals (440 Final approvals
and 29 tentative approvals) from USFDA.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.